国药现代：公司积极推进缓控释、膜剂等创新技术平台建设

Core Viewpoint - The company emphasizes its commitment to "technology-led, innovation-driven" strategies, focusing on accelerating technological innovation and advancing the development of improved new drugs and high-end complex formulations [1] Group 1: Technological Innovation - The company is actively promoting the construction of innovative technology platforms, including sustained-release and membrane dosage forms [1] - Collaboration with East China University of Science and Technology and other higher education institutions is ongoing in the field of synthetic biology [1] Group 2: Research and Development - Specific details regarding the company's R&D efforts will be disclosed in the relevant sections of the annual report [1]